Table 1: Demographics and clinical characteristics of study participants.
There were no significant differences in the clinical and demographic variables between groups.
| Baseline Characteristics of the Trial Participants | ||
|---|---|---|
| Characteristic | Colchicine (n=43) | Placebo (n=38) |
| Median age (IQR)-yr | 54.66 (45.0–60.7) | 52.0 (45.2–57.4) |
| Female sex-no. (%) | 9 (20.9) | 8 (21.1) |
| White, non-Hispanic-no. (%) | 8 (18.6) | 11 (29.0) |
| Black-no. (%) | 33 (76.7) | 26 (68.4) |
| Hispanic or other nonwhite race-no. (%) | 2 (4.7) | 1 (2.6) |
| Current smoker-no. (%) | 14 (33.3) | 13 (34.2) |
| Alcohol use-no. (%) | 26 (61.9) | 25 (67.6) |
| Median body-mass index (IQR) | 28.2 (24.9–31.7) | 27.3 (24.8–29.4) |
| Hypertension-no. (%) | 20 (47.6) | 15 (39.5) |
| Diabetes-no. (%) | 4 (9.5) | 1 (2.6) |
| Median LDL Cholesterol (IQR)-mg/dL | 98.5 (81.8–120.5) | 105 (81.5–127.0) |
| Median Triglycerides (IQR)-mg/dL | 100 (76.5–148.5) | 95 (83.8–134.8) |
| Median C-reactive protein level (IQR)- mg/liter | 1.7 (0.8–4.7) | 1.3 (0.9–2.7) |
| GFR ≥60-no. (%) | 42 (97.7) | 35 (92.1) |
| HIV Viral load log <1.30. (%) | 28 (66.7) | 21 (56.8) |
| HIV quant log value ≤ 20 copies/ml. (%) | 28 (66.7) | 22 (59.5) |
| Use of ACE inhibitor or ARB-no. (%) | 4 (9.3%) | 2 (5.3%) |
| Use of statin-no. (%) | 19 (44.2%) | 12 (31.6%) |
| Use of beta-blocker-no. (%) | 13 (30.2%) | 7 (18.4%) |
| Use of antiplatelet or antithrombotic agent-no. (%) | 0 (0%) | 0 (0%) |